Across Asia, health insurers are selling products priced against morbidity assumptions that the data is increasingly moving against. With chronic disease rising, medical cost trends running at double-digit rates, and regulators beginning to intervene, the repricing question is shifting from theoretical to operational.
The commercial stakes are specific. A December 2025 analysis of critical illness (CI) insurance across six Asian markets by Milliman found that most CI products in the region carry guaranteed-level premiums – meaning that when claims experience deteriorates, insurers absorb the loss on in-force business. Insurers are cautious about repricing due to concerns about negative publicity and fairness, especially as many CI policies are level premium and pre-funded, and as experience deteriorates, reinsurers have increased their CI rates within allowed treaty means, directly raising costs for primary insurers. The result is a structure under pressure from both sides: rising claims and rising reinsurance costs, with limited ability to adjust premiums on existing books.
The pressure is unevenly distributed. According to Mercer Marsh Benefits, projected medical trend rates for 2025 – the year-on-year increase in claims costs per insured person – reached 15% in Malaysia and Vietnam, 19% in Indonesia, and 21% in the Philippines, all well above both general inflation and most pricing assumptions embedded in long-dated guaranteed products. For the third consecutive year, health insurers in Asia-Pacific forecast double-digit medical cost inflation, with the region projected to record the highest medical cost increase globally.
The Swiss Re Institute’s 2025 Asia Life and Health Consumer Survey, covering more than 12,000 respondents across 12 markets, estimated that Asia’s health protection gap reached US$258 billion in premium equivalent terms in 2024, a 21% increase from 2017, with chronic conditions and critical illnesses contributing almost equally to household financial stress. The mortality protection gap for the same markets stood at US$132 billion, a 35% rise over the same period.
New research from AIA Group, published July 13, 2026, puts a specific face on the deteriorating morbidity picture. The report documents declining healthy life expectancy – years lived in good health beyond age 60 – across several key markets between 2019 and 2021: from 13.3 to 11.4 years in the Philippines, 13.8 to 11.9 years in Indonesia, 13.6 to 11.5 years in India, and 14.9 to 13.8 years in Malaysia. The AIA research argues that this deterioration is partly driven by non-biological factors – declining community participation, social isolation, and loss of purpose in later life – that traditional morbidity models do not capture. Stuart A. Spencer, AIA’s group chief marketing officer, framed it as an industry-wide challenge: “Life is more nuanced than the traditional risk factors insurers have employed. We need to extend our imagination and our curiosity to better understand seniors and appreciate how other factors contribute to improved mortality, morbidity, and longevity.” Whether or not insurers move to incorporate psychosocial variables into underwriting – no Asian regulator has yet required it – the underlying deterioration in healthspan is already flowing through to claims.
Indonesia’s Financial Services Authority (OJK) moved directly on health insurance sustainability in late 2025. In December 2025, the OJK issued POJK No. 36/2025, regulating the strengthening of the health insurance ecosystem in Indonesia, shortening the waiting period for critical illness benefits and restricting repricing of health products to once per year, with mandatory written notice to policyholders at least 30 days in advance. The regulation formalizes repricing rules in a market where projected medical cost trends remain elevated, increasing pressure on insurers’ pricing assumptions and product sustainability. The intervention reflects a regulatory recognition that the current product architecture – guaranteed premiums, annual repricing constraints, rising chronic disease burden – is structurally misaligned in high-trend markets.
In the absence of broader regulatory direction on underwriting reform, the industry is moving on post-issue strategies. PartnerRe, in a November 2025 analysis, identified preventive health screenings, wellness programs, and regular medical check-ins as tools to actively manage risk while promoting healthier lifestyles, noting that Singapore operates national schemes alongside private coverage while Hong Kong lacks a comparable government-backed senior framework – a gap that leaves private insurers more exposed there. WTW’s 2026 Asia-Pacific medical trends survey found that over half of insurers in the region expect elevated medical trends to persist for at least three years, with 64% planning to add wellbeing services to their health programs – the highest proportion of any global region surveyed.
The commercial logic of intervening earlier is explicit in AIA’s research: the report argues that healthspan-lengthening interventions are more durable the sooner they begin, extending the relevant audience to younger policyholders, not only seniors. For health and critical illness lines already under claims pressure, that framing has direct pricing implications – reducing future morbidity through behavioural intervention may be more cost-effective than absorbing it through guaranteed-premium books that cannot be repriced.
